Immunicum AB (IMMU)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Immunicum AB (IMMU)-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH314956D
  • |
  • Pages: 25
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Immunicum AB (Immunicum) is a biopharmaceutical company that develops therapeutic for treatment of cancer. The company's products comprise INTUVAX-RCC, INTUVAX-HCC, SUBCUVAX and CD70. Immunicum's CD70 is in a preclinical phase studies. It has partnerships with biotech and pharmaceutical companies, INTUVAX-RCC is a drug candidate used to treat Renal cell carcinoma, INTUVAX-HCC is used for treating liver cancer and SUBCUVAX is a drug candidate, which induces a tumor specific immune reaction in vitro. The company uses technologies such as COMBIG and CD70 to develop therapeutic cancer vaccines. Immunicum is headquartered in Gothenburg, Sweden.

Immunicum AB (IMMU)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 4

Immunicum AB, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 4

Immunicum AB, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6

Immunicum AB, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7

Immunicum AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8

Immunicum AB, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9

Immunicum AB, Pharmaceuticals & Healthcare, Deal Details 10

Asset Purchase 10

Immunicum Acquires Patent for Oncolytic Therapy from Virex for USD0.2 Million 10

Venture Financing 10

Immunicum Secures US$3.6 Million In Financing 10

Partnerships 11

Immunicum Enters into Agreement with Accelovance and Midwest Melanoma Partnership 11

Equity Offering 12

Immunicum Completes IPO 12

Immunicum Announces Private Placement Of Shares For US$1.3 Million 13

Immunicum AB-Key Competitors 14

Key Employees 15

Locations And Subsidiaries 16

Head Office 16

Recent Developments 17

Financial Announcements 17

Feb 17, 2017: Immunicum: Year-End Report 2016 (July 2016-December 2016) 17

Corporate Communications 20

Sep 27, 2016: Immunicum Announces Carlos de Sousa as New CEO to take the Company to its Next Stage of Development 20

May 02, 2016: Immunicum applies for listing on the Nasdaq Stockholm main market 21

Product News 22

11/14/2016: Immunicum Presented Poster at SITC Conference on INTUVAX HCC I/II clinical study-Announces Last Patient Included in Study Extension 22

Product Approvals 23

Jul 22, 2016: Immunicum Submits IND Application To The Food And Drug Administration For Approval To Treat Kidney Cancer Patients In The United States In Its Ongoing Phase II-Trial 23

Clinical Trials 24

Jun 23, 2016: Immunicum Announces Preliminary Plans to Initiate Clinical Trials with INTUVAX in Melanoma in both Sweden and the U.S. 24

Appendix 25

Methodology 25

About GlobalData 25

Contact Us 25

Disclaimer 25

List of Figures

Immunicum AB, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

Immunicum AB, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

Immunicum AB, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

Immunicum AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

Immunicum AB, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5

Immunicum AB, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 6

Immunicum AB, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7

Immunicum AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8

List of Tables

Immunicum AB, Pharmaceuticals & Healthcare, Key Facts, 2016 1

Immunicum AB, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5

Immunicum AB, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6

Immunicum AB, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7

Immunicum AB, Deals By Therapy Area, 2011 to YTD 2017 8

Immunicum AB, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9

Immunicum Acquires Patent for Oncolytic Therapy from Virex for USD0.2 Million 10

Immunicum Secures US$3.6 Million In Financing 10

Immunicum Enters into Agreement with Accelovance and Midwest Melanoma Partnership 11

Immunicum Completes IPO 12

Immunicum Announces Private Placement Of Shares For US$1.3 Million 13

Immunicum AB, Key Competitors 14

Immunicum AB, Key Employees 15

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Immunicum AB, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license

Single User License
USD 250 INR 16065
Site License
USD 500 INR 32130
Corporate User License
USD 750 INR 48195

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com